Paola Marcato

List of Publications by Year in Descending Order

66 papers	2,612 citations	28 h-index	50 g-index
70 ext. papers	2,977 ext. citations	6 avg, IF	5.02 L-index

#	Paper	IF	Citations
66	Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasis.. *Metabolomics*, **2022**, 18, 9	4.7	0
65	Breast Cancer Xenograft Murine Models. *Methods in Molecular Biology*, **2022**, 31-44	1.4	
64	Isolation of cancer stem cells from cultured breast cancer cells and xenografted breast tumors based on aldehyde dehydrogenase activity. *Methods in Cell Biology*, **2022**,	1.8	
63	The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.. *Frontiers in Oncology*, **2021**, 11, 791696	5.3	1
62	Human-specific GAPDH qRT-PCR is an accurate and sensitive method of xenograft metastasis quantification. *Molecular Therapy - Methods and Clinical Development*, **2021**, 20, 398-408	6.4	2
61	LncRNA Promotes Proliferation and Migration, Is Associated with Cancer Stem Cells, and Alters the miRNA Landscape in Triple-Negative Breast Cancer. *Cancers*, **2021**, 13,	6.6	2
60	An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer. *Molecular Oncology*, **2021**, 15, 2046-2064	7.9	0
59	Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR. *PLoS ONE*, **2021**, 16, e0251080	3.7	3
58	In Vivo Genome-Wide Pooled RNAi Screens in Cancer Cells to Identify Determinants of Chemotherapy/Drug Response. *Methods in Molecular Biology*, **2021**, 2381, 189-200	1.4	1
57	LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. *Cancer Letters*, **2021**, 509, 81-88	9.9	12
56	Datasets exploring putative lncRNA-miRNA-mRNA axes in breast cancer cell lines. *Data in Brief*, **2021**, 37, 107241	1.2	2
55	Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection. *Cancers*, **2021**, 13,	6.6	1
54	S100A10 Has a Critical Regulatory Function in Mammary Tumor Growth and Metastasis: Insights Using MMTV-PyMT Oncomice and Clinical Patient Sample Analysis. *Cancers*, **2020**, 12,	6.6	4
53	Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance. *Molecular Cancer Therapeutics*, **2020**, 19, 1110-1122	6.1	10
52	The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs. *Cells*, **2020**, 9,	7.9	16
51	ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells. *Cell Death and Differentiation*, **2020**, 27, 363-378	12.7	49
50	The Flick of a Switch: Conferring Survival Advantage to Breast Cancer Stem Cells Through Metabolic Plasticity. *Frontiers in Oncology*, **2019**, 9, 753	5.3	12

49	Phloridzin docosahexaenoate, a novel fatty acid ester of a plant polyphenol, inhibits mammary carcinoma cell metastasis. *Cancer Letters*, **2019**, 465, 68-81	9.9	11
48	TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway. *Scientific Reports*, **2019**, 9, 4182	4.9	21
47	Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells. *Scientific Reports*, **2019**, 9, 9414	4.9	19
46	TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem-Like Cells in a Redox-Sensitive Manner. *Clinical Cancer Research*, **2019**, 25, 2001-2017	12.9	13
45	Epigenetic Silencing of TAP1 in Aldefluor Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion. *Stem Cells*, **2018**, 36, 641-654	5.8	31
44	Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. *Frontiers in Immunology*, **2018**, 9, 654	8.4	27
43	Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. *Cancers*, **2018**, 10,	6.6	39
42	ALDH1A3 Is the Key Isoform That Contributes to Aldehyde Dehydrogenase Activity and Affects Proliferation in Cardiac Atrial Appendage Progenitor Cells. *Frontiers in Cardiovascular Medicine*, **2018**, 5, 90	5.4	11
41	DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid. *Cancers*, **2018**, 10,	6.6	15
40	Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL). *Cell Death and Disease*, **2018**, 9, 920	9.8	8
39	Hide-and-seek: the interplay between cancer stem cells and the immune system. *Carcinogenesis*, **2017**, 38, 107-118	4.6	62
38	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. *BioMed Research International*, **2017**, 2017, 9620870	3	32
37	Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE-independent mechanisms of gene expression. *Scientific Reports*, **2017**, 7, 16684	4.9	15
36	Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1. *Oncotarget*, **2016**, 7, 44096-44112	3.3	22
35	Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3. *Molecular Oncology*, **2016**, 10, 1485-1496	7.9	48
34	Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus. *Journal of Immunology*, **2015**, 194, 4397-412	5.3	26
33	Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. *Molecular Oncology*, **2015**, 9, 17-31	7.9	76
32	A STAT3-NFkB/DDIT3/CEBP□axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. *Oncotarget*, **2015**, 6, 12637-53	3.3	49

31	Cancer Stem Cells and Chemoresistance: Strategies to Overcome Therapeutic Resistance **2015**, 477-518		2
30	Targeting Key Stemness-Related Pathways in Human Cancers **2015**, 393-443		
29	Breast Cancer Genomics **2014**, 213-232		2
28	Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. *British Journal of Cancer*, **2014**, 110, 83-93	8.7	50
27	Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. *Neoplasia*, **2014**, 16, 950-60	6.4	52
26	Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. *Molecular Therapy*, **2013**, 21, 338-47	11.7	51
25	Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. *PLoS ONE*, **2013**, 8, e54006	3.7	19
24	Association of core needle biopsies with increase in metastatic dissemination of breast cancer.. *Journal of Clinical Oncology*, **2012**, 30, e21090-e21090	2.2	
23	Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. *Stem Cells*, **2011**, 29, 32-45	5.8	338
22	Oncolytic virus-initiated protective immunity against prostate cancer. *Molecular Therapy*, **2011**, 19, 797-804	11.7	62
21	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. *Cell Cycle*, **2011**, 10, 1378-84	4.7	367
20	Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. *Molecular Cancer Therapeutics*, **2010**, 9, 2924-33	6.1	84
19	Oncolytic reovirus effectively targets breast cancer stem cells. *Molecular Therapy*, **2009**, 17, 972-9	11.7	65
18	Host Signaling Responses to Reovirus Infection **2009**, 627-653		
17	Targeting cancer-initiating cells with oncolytic viruses. *Molecular Therapy*, **2009**, 17, 1677-82	11.7	70
16	The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. *Molecular Therapy*, **2007**, 15, 1531-6	11.7	65
15	Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. *Molecular Therapy*, **2007**, 15, 1522-30	11.7	130
14	Differential binding of Shiga toxin 2 to human and murine neutrophils. *Journal of Medical Microbiology*, **2007**, 56, 1423-1430	3.2	32

13	Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. *Journal of Infectious Diseases*, **2006**, 193, 1120-4	7	46
12	Basis for N-acetyllactosamine-mediated inhibition of enteropathogenic Escherichia coli localized adherence. *Journal of Medical Microbiology*, **2006**, 55, 669-675	3.2	27
11	Binding of adenine to Stx2, the protein toxin from Escherichia coli O157:H7. *Acta Crystallographica Section F: Structural Biology Communications*, **2006**, 62, 627-30		23
10	Connecting reovirus oncolysis and Ras signaling. *Cell Cycle*, **2005**, 4, 556-9	4.7	34
9	Stability of the homopentameric B subunits of shiga toxins 1 and 2 in solution and the gas phase as revealed by nanoelectrospray fourier transform ion cyclotron resonance mass spectrometry. *Journal of the American Society for Mass Spectrometry*, **2005**, 16, 1957-68	3.5	28
8	Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. *Oncogene*, **2005**, 24, 7720-8	9.2	72
7	Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. *Infection and Immunity*, **2005**, 73, 6523-9	3.7	38
6	Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. *Journal of Infectious Diseases*, **2003**, 187, 640-9	7	130
5	Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt's lymphoma B cells. *Infection and Immunity*, **2003**, 71, 4828	3.7	3
4	Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer. *Infection and Immunity*, **2003**, 71, 6075-8	3.7	26
3	Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt's lymphoma B cells. *Infection and Immunity*, **2002**, 70, 1279-86	3.7	25
2	Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. *Journal of Infectious Diseases*, **2001**, 183, 435-43	7	72
1	Glycan mimicry as a basis for novel anti-infective drugs. *Biochimie*, **2001**, 83, 841-7	4.6	51